Catherine A. Srebalus Barnes, PhD Pfizer, Inc

Catherine is the Senior Director for the Pfizer Biosimilars Analytical R&D group.  She joined Pfizer as part of the Hospira acquisition in September 2015.  Catherine’s Pfizer team is responsible for definition and implementation of strategies for demonstration of analytical similarity between Pfizer biosimilar products and on-market originator products.  Additional responsibilities include analytical method development, qualification/validation and definition/implementation of analytical control strategies for biosimilar products.  She is actively involved in the preparation of global regulatory submissions and meetings with Global Health Authorities in support of Pfizer’s biosimilar programs.

Prior to joining Hospira in 2012, Catherine held a number of roles in the Bioproduct Development organization at Eli Lilly and Company, including Director, Bioproduct Analytical Development and Director, Bioprocess Purification Development and Viral Safety.  As Director, Bioproduct Analytical Development, Catherine led a group of scientists responsible for overseeing the development of analytical methods and control strategies for therapeutic proteins and peptides.  As Director, Bioprocess Purification Development and Viral Safety at Lilly, Catherine led a group of scientists and engineers responsible for overseeing purification process development/optimization and technology transfer activities for biotechnology products in clinical and commercial development.

Catherine has a B.S. in Chemistry (West Virginia University, U.S.A.) and a Ph.D. in Analytical Chemistry (Indiana University, U.S.A).